These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38011186)

  • 21. The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma.
    Mackiewicz J; Rybarczyk-Kasiuchnicz A; Łasińska I; Mazur-Roszak M; Świniuch D; Michalak M; Kaźmierska J; Studniarek A; Krokowicz Ł; Bajon T
    Medicine (Baltimore); 2017 Dec; 96(51):e9151. PubMed ID: 29390445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of Swallowing Function in Patients with Head and Neck Squamous Cell Carcinoma in High vs. Low Dose Cisplatin.
    Veldman A; van Oosbree A; Braun M; Gurumoorthy A; Spanos WC; Powell S
    Cancer Invest; 2023 Dec; 41(10):807-815. PubMed ID: 37962276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin Weekly Versus Every 3 Weeks Concurrently with Radiotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinomas: What Is the Best Dosing and Schedule?
    Mashhour K; Hashem W
    Asian Pac J Cancer Prev; 2020 Mar; 21(3):799-807. PubMed ID: 32212810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
    Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
    Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma.
    Chera BS; Sheth SH; Patel SA; Goldin D; Douglas KE; Green RL; Shen CJ; Gupta GP; Moore DT; Grilley Olson JE; Weiss JM
    Cancer; 2021 Dec; 127(23):4447-4454. PubMed ID: 34379792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regional control after concomitant chemoradiotherapy without planned neck dissection in node-positive head and neck squamous cell carcinomas.
    Sakashita T; Homma A; Oridate N; Suzuki S; Hatakeyama H; Kano S; Mizumachi T; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
    Auris Nasus Larynx; 2013 Apr; 40(2):211-5. PubMed ID: 22867524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial on acute toxicities of weekly vs three-weekly cisplatin-based chemoradiation in head and neck cancer.
    Ameri A; Norouzi S; Sourati A; Azghandi S; Novin K; Taghizadeh-Hesary F
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1425. PubMed ID: 34101389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.
    Cavalieri S; Platini F; Barretta F; Nuzzolese I; Ottini A; Bergamini C; Resteghini C; Colombo E; Iacovelli NA; Franceschini M; Calareso G; Di Pede P; De Feo G; Gandelli M; Toffolatti L; Guglielmo M; Ripamonti CI; Cosmai L; Licitra L; Alfieri S
    Oral Oncol; 2023 Nov; 146():106579. PubMed ID: 37778228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer: A systematic review and meta-analysis endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
    De Felice F; Belgioia L; Alterio D; Bonomo P; Maddalo M; Paiar F; Denaro N; Corvò R; Merlotti A; Bossi P; Pappagallo GL; D' Angelillo RM; Magrini SM; Arcangeli S
    Crit Rev Oncol Hematol; 2021 Jun; 162():103345. PubMed ID: 33933569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
    Sun XS; Tao Y; Le Tourneau C; Pointreau Y; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Zubel A; Zanna C; Brienza S; Crompton P; Rouits E; Gollmer K; Szyldergemajn S; Bourhis J
    Lancet Oncol; 2020 Sep; 21(9):1173-1187. PubMed ID: 32758455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcome and morbidity after treatment with accelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer: results of a multidisciplinary late morbidity clinic.
    Rütten H; Pop LA; Janssens GO; Takes RP; Knuijt S; Rooijakkers AF; van den Berg M; Merkx MA; van Herpen CM; Kaanders JH
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):923-9. PubMed ID: 21095074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
    Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
    BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.
    Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H
    Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02).
    Lee JY; Sun JM; Oh DR; Lim SH; Goo J; Lee SH; Kim SB; Park KU; Kim HK; Hong DS; Kim JS; Kim SG; Yi SY; Yun HJ; Hyun MS; Kim HJ; Jung SH; Park K; Ahn YC; Ahn MJ
    Radiother Oncol; 2016 Feb; 118(2):244-50. PubMed ID: 26705681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer.
    Fury MG; Lee NY; Sherman E; Ho AL; Rao S; Heguy A; Shen R; Korte S; Lisa D; Ganly I; Patel S; Wong RJ; Shaha A; Shah J; Haque S; Katabi N; Pfister DG
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):479-86. PubMed ID: 24074921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weekly cisplatin concurrently with radiotherapy in head and neck squamous cell cancer: a retrospective analysis of a tertiary institute experience.
    Osman N; Elamin YY; Rafee S; O'Brien C; Stassen LF; Timon C; Kinsella J; Brennan S; O'Byrne KJ
    Eur Arch Otorhinolaryngol; 2014 Aug; 271(8):2253-9. PubMed ID: 24121822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
    van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
    BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinoma.
    Morse RT; Ganju RG; TenNapel MJ; Neupane P; Kakarala K; Shnayder Y; Chen AM; Lominska CE
    Head Neck; 2019 Aug; 41(8):2492-2499. PubMed ID: 30856297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary concurrent chemoradiation therapy with triweekly cisplatin as a standard protocol in patients aged ≥65 years with head and neck squamous cell carcinoma.
    Ahn D; Kwak JH; Lee GJ; Sohn JH; Lee JE
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e239-e247. PubMed ID: 36178306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.